Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Satellos Bioscience ( (TSE:MSCL) ) just unveiled an announcement.
Satellos Bioscience filed its Form 6-K for May 2026, reporting unaudited condensed consolidated interim financial statements for the quarter ended March 31, 2026, along with management’s discussion and analysis and related officer certifications. For the first quarter, the company expanded its balance sheet to total assets of $75.2 million, driven by higher cash and short-term investments, while posting a net loss of $9.8 million as R&D and administrative expenses rose year-on-year, highlighting an intensified spend profile typical of a development-stage biotech and underscoring ongoing financing needs for shareholders to monitor.
The filing also shows shareholders’ equity more than doubled to $70.7 million from $27.8 million at year-end 2025, primarily through increases in common share capital and pre-funded warrants. With liabilities remaining modest at $4.6 million and finance income partly offsetting operating losses, the update confirms a strengthened capital position alongside higher burn, positioning Satellos to continue advancing its programs but maintaining execution and funding risk for investors.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$23.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on MSCL Stock
According to Spark, TipRanks’ AI Analyst, MSCL is a Neutral.
The score is mainly held back by weak financial performance (no revenue, ongoing losses, and sustained cash burn), only partly offset by a debt-free balance sheet. Technicals are mixed with negative MACD despite the price holding above several key moving averages, and valuation is constrained by a negative P/E and no dividend.
To see Spark’s full report on MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a Toronto-based biopharmaceutical company focused on developing therapies, supported by significant investment in research and development. The company is listed in the U.S. as a foreign private issuer and reports under Canadian and U.S. securities regimes, reflecting an international capital markets focus.
Average Trading Volume: 24,921
Technical Sentiment Signal: Sell
Current Market Cap: C$207.7M
Find detailed analytics on MSCL stock on TipRanks’ Stock Analysis page.